Amneal launches generic Butrans

Patients with severe pain have a new generic treatment available.

Amneal has released generic Butrans (buprenorphine transdermal system), in dosage strengths of 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr., following approval by the Food and Drug Administration.

Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

“Expanding our portfolio of complex generic drug products and providing patients access to affordable generic medicines will continue to set Amneal apart," Amneal co-CEOs Chirag Patel and Chintu Patel said in a statement. "Buprenorphine represents the fifth complex product approval we have achieved in the last few months and demonstrates continued progress in our shift to commercialize more complex, high-value products. Our employees have demonstrated incredible resolve in helping us achieve these milestones during an unprecedented time.”

Butrans had a market value of approximately $225 million for the 12 months ended February 2020, according to IQVIA.